CureVac NV Valuation
| CVAC Stock | USD 3.21 0.04 1.26% |
At this time, the firm appears to be undervalued. CureVac NV shows a prevailing Real Value of $3.46 per share. The current price of the firm is $3.21. Our model approximates the value of CureVac NV from analyzing the firm fundamentals such as Return On Equity of -0.54, shares outstanding of 224.34 M, and Operating Margin of (4.94) % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that CureVac NV's price fluctuation is risky at this time. Calculation of the real value of CureVac NV is based on 3 months time horizon. Increasing CureVac NV's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since CureVac NV is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CureVac Stock. However, CureVac NV's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.21 | Real 3.46 | Hype 3.21 | Naive 3.44 |
The real value of CureVac Stock, also known as its intrinsic value, is the underlying worth of CureVac NV Company, which is reflected in its stock price. It is based on CureVac NV's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of CureVac NV's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of CureVac NV helps investors to forecast how CureVac stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CureVac NV more accurately as focusing exclusively on CureVac NV's fundamentals will not take into account other important factors: CureVac NV Total Value Analysis
CureVac NV is currently forecasted to have valuation of 194.41 M with market capitalization of 711.15 M, debt of 41.82 M, and cash on hands of 540.87 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the CureVac NV fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
194.41 M | 711.15 M | 41.82 M | 540.87 M |
CureVac NV Investor Information
About 45.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.97. Some equities with similar Price to Book (P/B) outperform the market in the long run. CureVac NV has Price/Earnings To Growth (PEG) ratio of 0.07. The entity had not issued any dividends in recent years. Based on the key indicators related to CureVac NV's liquidity, profitability, solvency, and operating efficiency, CureVac NV is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.CureVac NV Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. CureVac NV has an asset utilization ratio of 6.82 percent. This indicates that the Company is making $0.0682 for each dollar of assets. An increasing asset utilization means that CureVac NV is more efficient with each dollar of assets it utilizes for everyday operations.CureVac NV Ownership Allocation
CureVac NV holds a total of 224.34 Million outstanding shares. CureVac NV retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.CureVac NV Profitability Analysis
The company reported the previous year's revenue of 53.76 M. Net Loss for the year was (260.17 M) with loss before overhead, payroll, taxes, and interest of (86.28 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates CureVac NV's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in CureVac NV and how it compares across the competition.
About CureVac NV Valuation
The stock valuation mechanism determines CureVac NV's current worth on a weekly basis. Our valuation model uses a comparative analysis of CureVac NV. We calculate exposure to CureVac NV's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of CureVac NV's related companies.CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. Curevac NV operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 764 people.
CureVac NV Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 220.8 M | |
| Forward Price Earnings | 5.2356 |
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |